Treatment Switch to Dolutegravir With 2 Nucleoside Reverse-Transcriptase Inhibitors (NRTI) in Comparison to Continuation With Protease Inhibitor/Ritonavir Among Patients With Human Immunodeficiency Virus at Risk for Prior NRTI Resistance: A Cohort Analysis of Real-World Data

BACKGROUND: Switching antiretroviral regimens when human immunodeficiency virus (HIV) viremia is controlled for a new regimen is challenging when there is the potential for prior nucleoside reverse-transcriptase inhibitor (NRTI) resistance. The objective was to study virologic outcomes after switchi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sangaré, Mohamed N’dongo, Baril, Jean-Guy, de Pokomandy, Alexandra, Ferreira Guerra, Steve, Carabali, Mabel, Laprise, Claudie, Thomas, Réjean, Klein, Marina, Tremblay, Cécile, Roger, Michel, Pexos, Costa, Greenwald, Zoë R, Machouf, Nima, Durand, Madeleine, Hardy, Isabelle, Dakouo, Mamadou, Trevisan, Andrea, Laporte, Louise, Schnitzer, Mireille E, Trottier, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Major Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654378/
https://www.ncbi.nlm.nih.gov/pubmed/33204746
http://dx.doi.org/10.1093/ofid/ofaa404

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654378/
https://www.ncbi.nlm.nih.gov/pubmed/33204746
http://dx.doi.org/10.1093/ofid/ofaa404

Ejemplares similares